Irbesartan, Losartan and Valsartan (Azido Impurity) Class Action

All persons resident in Canada who were prescribed, purchased and/or ingested certain Sartans manufactured and/or packaged by the Defendants that have been recalled due to the presence of an azido impurity above acceptable limits, and their beneficiaries (the “Class Members”) pursuant to the Family Compensation Act, R.S.B.C. 1996, c. 126.

Current Status
Overview

Current Status

The Irbesartan Class Action is in the process of being dismissed as a result of the ruling in Palmer v. Teva Canada Limited, 2024 ONCA 220 (CanLII), https://canlii.ca/t/k3q9w. RHE will update this website to indicate the date on which the case is formally dismissed.

As of this date, class members need to take their own steps if they wish to advance their claims for Irbesartan related damages. Class members should be aware that limitation periods may commence running pursuant to s. 39 of the Class Proceedings Act. Class members should consider immediately seeking legal advice and assistance on:

1. Commencing their own claims in the Provincial Superior Court where they reside;

2. Contacting counsel to assist them with such claims.

As our case will be dismissed, RHE cannot provide further assistance to Irbesartan claimants. We encourage you to take the steps above if you believe you have an injury caused by these Defendants.

Overview

This proposed class action arises out of concerns for Irbesartan, Losartan and Valsartan medications (“Sartans”), all of which are angiotensin receptor blockers, which are a class of drugs used to treat patients with high blood pressure to help prevent heart attacks and stroke. They are also used in patients with heart failure or those who have had a recent heart attack.

The claim alleges that an azido impurity, (5-(4′-(azidomethyl)-[1,1′-biphenyl]-2yl)-1H-tetrazole) has been detected in certain Sartans manufactured, distributed and sold by the Defendants at levels higher than recommended under established international guidelines. The azido impurity is considered a mutagen – a chemical substance that can cause a change in the DNA of a cell. These mutations may increase the risk of cancer.

A link to the Health Canada recall can be found here.

Please see the Notice of Civil Claim for more details.

A full list of the affected products are listed here.

IRBESARTAN, LOSARTAN AND VALSARTAN (AZIDO IMPURITY) FORM

Note: If you received any of the above-listed drugs, you may be affected by this class action lawsuit. Please fill out the form below to get in touch with us. Joining our contact list creates no financial obligation and we will keep all the information that you provide to us confidential.

I provide my consent and agree herein to receive communications from RHE LLP, which may include announcements regarding class actions, practice updates, newsletters, publications, event invitations or other information that may be of interest. I understand that consent to receive these electronic communications may be withdrawn at any time by emailing reception@rhelaw.com.

Class Action Form

Contact Information

First Name

Last Name

Email *

Phone

FAX

Address (unit no., building/house number, street name) *

City/Town *

Province *

Postal Code *

Subject *

Date of Birth *

Personal Health Number *

Date of Prescription *

Date of Purchase?

Date Started?

Name of Product Purchased *

Package Warnings

Date Onset

Date that you sought medical treatment for your symptoms

Symptoms *

Other Comments

Consent

I provide my consent and agree herein to receive communications from RHE LLP, which may include announcements regarding class actions, practice updates, newsletters, publications, event invitations or other information that may be of interest. I understand that I can unsubscribe to these emails at any time. I understand that some of the personal information that I provide may be stored or processed outside of British Columbia and/or Canada, on a US server, and will be kept confidential, subject to the potential that a foreign state may seek to access the data for “lawful access” purposes. If you have any questions about RHE’s policies and practices regarding service providers outside Canada, or about the collection, use, disclosure or storage of personal information by the service providers outside Canada, please contact reception@rhelaw.com.

Custom Captcha *